Cytotoxicity.

Chocolate is a widely enjoyed commodity across all age groups however doctors often advise against its consumption for individuals with conditions such as diabetes, high blood pressure, obesity, and coronary artery disease. This study aimed to develop a medicated chocolate that not only allows patients to enjoy chocolate but also helps prevent diabetes. Mangifera indica (mango leaves) is known for its antidiabetic properties due to its high concentration of antioxidants, vitamins, polyphenols, and flavonoids, which aid in lowering blood sugar levels. The formulation of antidiabetic chocolate was achieved using an hydroalcoholic extract of Mangifera indica, Cocoa powder, Cocoa butter, Monk fruit, and Erythritol in optimized proportions. The chocolate was then evaluated based on physical parameters such as appearance, taste, odour, consistency, blooming test, physical stability, and drug content determination using UV spectroscopy. Additionally, an MTT assay was conducted against INS-1 832/3 cell lines, with Metformin as the standard, to assess cell proliferation and cytotoxicity. The study successfully incorporated mango leaf powder into chocolate, masking the unpleasant taste of the medicinal components while maintaining a smooth, silky texture. The results indicated that the formulated chocolate was safe for consumption without posing any risk of adverse effects.

In this study, we formulated and investigated the effects of Temozolomide (TM)/Poly (lactide-co-glycolide) (PLGA) nanoparticles on the behaviour of C6 glioma cells. The nanoparticles were fabricated by the emulsifying solvent evaporation, and they were characterized by using X-Ray diffraction, scanning electron microscopy (SEM), transmission electron microscopy (TEM). Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) showed that such nanoparticles had a smooth surface and a spherical geometry. Powder X-ray diffraction (XRD) results indicated that TM trapped in the nanoparticles existed in an amorphous or disordered-crystalline status in the polymer matrix. The release profiles of Temozolomide from nanoparticles resulted in biphasic patterns. After an initial burst, a continuous drug release was observed for up to 1 month. Finally, a cytotoxicity test was performed using Glioma C6 cancer cells to investigate the cytotoxicity of Temozolomide delivered from PLGA nanoparticles. It has been found that the cytotoxicity of Temozolomide to Glioma C6 cancer cells is enhanced when TM is delivered from PLGA polymeric carrier and while Temozolomide powder shows activity only up to 12 hours, where as Temozolomide loaded PLGA nanoparticles shows cytotoxicity in much more enhanced way.